adjuvant

(redirected from Adjuvant treatment)
Also found in: Dictionary, Thesaurus, Medical.
Related to Adjuvant treatment: palliative treatment

adjuvant

[′aj·ə·vənt]
(pharmacology)
A material that enhances the action of a drug or antigen.
Mentioned in ?
References in periodicals archive ?
The new indication is for the adjuvant treatment of patients "with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy."
Ipilimumab approved as adjuvant melanoma therapy
EXETER, ENGLAND -- Adjuvant treatment with mistletoe extract can increase the tolerability of conventional cancer treatment, improve patient quality of life, and lengthen tumor-free survival, Dr.
Mistletoe improves tolerability of breast cancer treatment. (Multicenter Cohort Study)
The Oncologic Drugs Advisory Committee recommended that the agent be approved for sequential administration following doxorubicin-containing therapy for the adjuvant treatment of women with node-positive breast cancer.
FDA Advisory Panel Approves New Use for Taxol
M2 PHARMA-March 20, 2019-Puma Viotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize Nerlynx for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Puma Viotechnology's Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize Nerlynx for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Puma Biotechnology filed a new drug submission for NERLYNX with Health Canada in July 2018 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy.
Puma Biotechnology, Knight Therapeutics enter into license agreement for NERLYNX
Merck announced that the European Commission has approved KEYTRUDA, the company's anti-PD-1 therapy, for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection.
Merck: EC approves KEYTRUDA for treatment of stage III melanoma
The Perjeta-based regimen is already approved in the US and several other countries for adjuvant treatment of HER2-positive eBC at high risk of recurrence.
Roche receives European Commission approval for Perjeta in combination with Herceptin and chemotherapy
Genentech, a member of the Roche Group, announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla as a single agent significantly reduced the risk of disease recurrence or death by 50% compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment.
Roche announces Phase 3 KATHERINE study met its primary endpoint
M2 EQUITYBITES-May 1, 2018-Novartis wins US FDA approval for Tafinlar & Mekinist combination for adjuvant treatment of patients with melanoma
Novartis wins US FDA approval for Tafinlar & Mekinist combination for adjuvant treatment of patients with melanoma

Encyclopedia browser ?
Full browser ?